Genmab wisely chose not to pursue GEN3014 further, focusing instead on its existing pipeline projects. Click here to read an ...

Citigroup started coverage on shares of BioNTech (NASDAQ:BNTX – Free Report) in a report issued on Thursday morning, Marketbeat Ratings reports. The brokerage issued a buy rating and a $145.00 target ...

Analysts at HC Wainwright issued their FY2024 earnings per share (EPS) estimates for shares of BioNTech in a research report ...

Fintel reports that on March 13, 2025, Citigroup initiated coverage of BioNTech SE - Depositary Receipt () (NasdaqGS:BNTX) ...

Shares of Telecommunications sector company AT&T moved 2.7% today, and are now trading at a price of $26.41. The Large-Cap ...

BioNTech SE ( NASDAQ:BNTX ) just released its full-year report and things are looking bullish. Results overall ...

Deutsche Bank analyst Emmanuel Papadakis maintained a Buy rating on BioNTech SE (BNTX – Research Report) today and set a price target of ...

Q4 2024 Earnings Call Transcript March 10, 2025 Operator: Welcome to BioNTech’s Fourth Quarter and Full-Year 2024 Earnings ...

German biotech company BioNTech announced a financial loss of €665.3 million ($721 million) for 2024, attributing the decline ...

German biotech company BioNTech announced a loss of EURO665.3 million (USD721 million) in 2024, due to the decline of ...

周一，Jefferies重申了对BioNTech SE（NASDAQ:BNTX）的股票评级和目标价，维持买入评级，目标价为149.00美元。此次重申是在该公司最新季度财报发布后做出的。财报显示，公司收入约为11.9亿欧元，略高于市场预期的11.8亿欧元。得益于运营支出的降低，每股收益（EPS）达到1.08欧元，同样超过了市场预期的0.77欧元。根据 InvestingPro ...

German biotech firm's revenues down 27% compared to 2023, according to company's financial report - Anadolu Ajansı ...